Baicalein Prevents Fructose-Induced Hepatic Steatosis in Rats: In the Regulation of Fatty Acid De Novo Synthesis, Fatty Acid Elongation and Fatty Acid Oxidation
Overview
Affiliations
Non-alcoholic fatty liver disease (NAFLD), ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), hepatic fibrosis and even hepatocellular carcinoma, is a liver disease worldwide without approved therapeutic drugs. Baicalein (BAL), a flavonoid compound extracted from the Traditional Chinese Medicine (TCM) Scutellariae Radix ( Georgi.), has been used in TCM clinical practice for thousands of years to treat liver diseases due to its "hepatoprotective effect". However, the underlying liver-protecting mechanisms remain largely unknown. Here, we found that oral administration of BAL significantly decreased excess serum levels of triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), aspartate aminotransferase (AST) as well as hepatic TG in fructose-fed rats. Attenuation of the increased vacuolization and Oil Red O staining area was evident on hepatic histological examination in BAL-treated rats. Mechanistically, results of RNA-sequencing, western-blot, real-time quantitative PCR (RT-qPCR) and hepatic metabolomics analyses indicated that BAL decreased fructose-induced excessive nuclear expressions of mature sterol regulatory element-binding protein 1c (mSREBP1c) and carbohydrate response element-binding protein (ChREBP), which led to the decline of lipogenic molecules [including fatty acid synthase (FASN), stearoyl-CoA desaturase 1 (SCD1), elongation of very long chain fatty acids 6 (ELOVL6), acetyl-CoA carboxylase (ACC)], accompanying with the alternation of hepatic fatty acids composition. Meanwhile, BAL enhanced fatty acid oxidation by activating AMPK/PGC1α signaling axis and PPARα signal pathway, which elicited high expression of carnitine palmitoyl transferase 1α (CPT1α) and Acyl-CoA oxidase 1 (ACO1) in livers of fructose-fed rats, respectively. BAL ameliorated fructose-induced hepatic steatosis, which is associated with regulating fatty acid synthesis, elongation and oxidation.
Cai Y, Fang L, Chen F, Zhong P, Zheng X, Xing H J Pharm Anal. 2025; 15(1):101052.
PMID: 40034684 PMC: 11873010. DOI: 10.1016/j.jpha.2024.101052.
Li P, Wang T, Qiu H, Zhang R, Yu C, Wang J Int J Mol Sci. 2024; 25(20).
PMID: 39457074 PMC: 11508832. DOI: 10.3390/ijms252011289.
Feng X, Zhang R, Yang Z, Zhang K, Xing J J Clin Transl Hepatol. 2024; 12(9):815-826.
PMID: 39280069 PMC: 11393839. DOI: 10.14218/JCTH.2024.00019.
Tan H, Mi N, Tong F, Zhang R, Abudurexiti A, Lei Y Food Sci Nutr. 2024; 12(8):5357-5372.
PMID: 39139977 PMC: 11317671. DOI: 10.1002/fsn3.4176.
Current strategies for nonalcoholic fatty liver disease treatment (Review).
Sun J, Jin X, Li Y Int J Mol Med. 2024; 54(4).
PMID: 39129305 PMC: 11335354. DOI: 10.3892/ijmm.2024.5412.